etrumadenant (AB928)

News alerts, weekly reports and conference planners

Company:

Arcus Biosci, Gilead, Otsuka

Drug class:

Adenosine A2A receptor antagonist, Adenosine A2B receptor antagonist

Related drugs:

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	zimberelimab + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB928 Sensitive : C2	zimberelimab + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB928 Sensitive : C2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	zimberelimab + AB154 + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 + AB928 Sensitive : C2	zimberelimab + AB154 + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 + AB928 Sensitive : C2

Associations
(2)